Vaishali Pharma Limited (VAISHALI) fair value: what the stock is really worth
As of Nov 16, 2026: fair value (intrinsic value) of Vaishali Pharma Limited stock ₹2.60, price ₹7.02, that is 62.9% below the price, quality 30 out of 100. Rating: strongly overvalued. Calculated from audited financials with 15 of our 26 valuation models and 37 quality factors, updated daily.
- Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free
Vaishali Pharma Limited
VAISHALI · NSEFar too expensive (fair value 63% below the price), weak company and falling price: meets none of the 3 rules.
What runs behind every stock
69 individual criteria per stock, every one traceable See the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 16, 2026.
How to read this chart
60‑month range ₹4.88 – ₹42.57 · fair‑value band ₹1.68 – ₹3.86 · the ₹7.02 price screens above the ₹2.60 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 16, 2026.
Every Wednesday you see whether Vaishali Pharma is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Company profile
Vaishali Pharma Limited engages in the pharmaceutical business in India and internationally.
Show moreShow less
It offers a portfolio of active pharmaceutical ingredients, such as antibiotics, anti-ulcer, anti-inflammatory, analgesic, anti-pyretic, topical steroids, anti"malarial, cardiac, corticosteroids, anti-diabetics, anti-cold, anti-allergic, anti-diarrheal, anti-protozoal, anti-parasitic, excipients, anti-viral, anti-epileptic, anti-asthmatic, enzymes, anti-fungal, anti-platelet agent, skeletal muscle relaxant, and anti-helminitic.
The company also provides formulations, including antibiotics, antibacterial, anti-platelet, laxative, anti-ulcer, enzymes, anti-asthmatic, anti-malarial, anti-cold, anti-allergic, anti-viral, anti-psychotic, anti-fungal, vitamins, topical steroids, corticosteroids, anti-inflammatory, analgesic, anti-pyretic, anti-diabetic, cardiac, and other products.
In addition, it offers disposable surgical and casting tape products; herbal products; veterinary products; nutraceutical products; and oncology products. The company was formerly known as Vaishali Pharma Private Limited. Vaishali Pharma Limited was founded in 1989 and is based in Mumbai, India.
Stock analysis
Vaishali Pharma Limited (VAISHALI) currently trades at ₹7.02, while our model-based Fair Value estimate is ₹2.60, 63% below the price, so the stock looks overvalued today.
Show more
Valuation
Bull case: the Growth Earnings group reads highest at a median of ₹6.28 per share, and 2 of the 15 models we run sit above the ₹7.02 price.
Bear case: the Earnings-Based group reads lowest at ₹2.24, and 13 of the 15 models stay below the price. Data coverage for this calculation is low.
Scenario range: ₹1.68 (bear) to ₹3.86 (bull), the price of ₹7.02 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 30/100 (below-average quality), in the Healthcare sector.
Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Vaishali Pharma Limited reported revenue of ₹1.1B in FY2026 versus ₹758M in FY2022, a compound +9.4%/yr. Reported net income was ₹41.6M in FY2026, compounding +0.9%/yr from FY2022.
Key figures
Market cap ₹914M (≈ $9.7M) Micro · P/S ratio 0.84 · Net margin 3.8% · Return on equity 6.2% · Return on assets (EBIT) 5.3% (5-year average) · Operating margin 5.9% · Revenue (TTM) ₹1.1B · Revenue growth (YoY) −3.6%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 33 out of 100 (low confidence).
What moves the price
The share trades about 28% below its 52-week high and 44% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −27% fair-value upside, at −63%, VAISHALI screens richer than that median.
Fair Value models
All 15 models by family
The fair value above starts from this blend and is adjusted for dilution from new shares.
Quality Score breakdown
It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.
Revenue & earnings trend
VAISHALI screens overvalued: fair value 63% below the price. Compare with Merck KGaA →
Compare Vaishali Pharma Limited with another stock
Price, fair value, quality and upside side by side.
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Drug Manufacturers - Specialty & Generic · 604 stocks
Valuation Multiplesvs Drug Manufacturers - Specialty & Generic median · lower = cheaper
Strength profile in five axes (Snowflake)
VALUE 0: the price sits above our fair-value range.
Context: sector, industry, market
- Is the Health Care sector expensive or cheap?
- P/E, EV/EBITDA and margins by industry (reference tables)
- Return on assets by industry
- Fair value gap by industry
- Piotroski F-Score screener with fair value
- Undervalued stocks: Indian Stocks
- Valuation of the India market
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
Similar stocks
10 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate.
| Stock | Price | Fair Value | vs Fair Value | Compare |
|---|---|---|---|---|
| Zoetis Inc ZTS | $84.39 | $113.53 | +35% | vs VAISHALI |
| Jiangsu Hengrui Pharmaceuticals Co 600276 | ¥48.02 | ¥53.04 | +10% | vs VAISHALI |
| Sun Pharmaceutical Industries Limited SUNPHARMA | ₹1,868 | ₹1,983 | +6% | vs VAISHALI |
| Haleon plc HLN | $9.20 | $8.47 | −8% | vs VAISHALI |
| Merck KGaA MRK | €149.70 | €108.83 | −27% | vs VAISHALI |
| Galderma Group GALD | CHF 191.00 | CHF 112.46 | −41% | vs VAISHALI |
| Takeda Pharmaceutical Company TAK | $21.59 | $11.23 | −48% | vs VAISHALI |
| Teva Pharmaceutical Industries Limited TEVA | $42.57 | $20.74 | −51% | vs VAISHALI |
| Sandoz Group SDZ | CHF 84.60 | CHF 40.54 | −52% | vs VAISHALI |
| Divi's Laboratories Limited DIVISLAB | ₹11,080 | ₹1,567 | −86% | vs VAISHALI |
Explore undervalued stocks
More undervalued Healthcare stocks →
Try a ready-made strategy
Pick a strategy and jump into the live analysis with that exact screen applied.
Discover tools
Frequently asked questions
Is Vaishali Pharma Limited (VAISHALI) overvalued or undervalued?
What is the fair value of VAISHALI?
What is the quality score of VAISHALI?
What is the price target for Vaishali Pharma Limited (VAISHALI)?
What is the Vaishali Pharma Limited stock forecast for 2026?
What is the revenue of Vaishali Pharma Limited (VAISHALI)?
What is the intrinsic value of Vaishali Pharma Limited (VAISHALI)?
Is Vaishali Pharma Limited stock overvalued or undervalued in 2026?
Is fair value the same as the market price of VAISHALI?
How much is Vaishali Pharma Limited worth?
What do the bullish and bearish scenarios say about VAISHALI?
How solid is the balance sheet of Vaishali Pharma Limited (VAISHALI)?
How far is VAISHALI from its 52-week high?
Which stocks are comparable to Vaishali Pharma Limited?
Is Vaishali Pharma Limited stock attractive at the current price?
How is the fair value of VAISHALI calculated?
Is it still worth investing in stocks now?
What is the share price of Vaishali Pharma Limited (VAISHALI)?
What should I pay attention to with Vaishali Pharma Limited right now?
Key figures of Vaishali Pharma Limited
How large is the market capitalisation of Vaishali Pharma Limited (VAISHALI)?
What is the P/S ratio of Vaishali Pharma Limited (VAISHALI)?
What is the net margin of Vaishali Pharma Limited (VAISHALI)?
What is the return on equity of Vaishali Pharma Limited (VAISHALI)?
What is the EBIT return on assets of Vaishali Pharma Limited (VAISHALI)?
What is the operating margin of Vaishali Pharma Limited (VAISHALI)?
How fast is revenue growing at Vaishali Pharma Limited (VAISHALI)?
How fast are earnings growing at Vaishali Pharma Limited (VAISHALI)?
How much free cash flow does Vaishali Pharma Limited (VAISHALI) generate?
How much net debt does Vaishali Pharma Limited (VAISHALI) carry?
Watch Vaishali Pharma Limited in the live analysis
One click puts Vaishali Pharma Limited on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Watch for free →Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.